Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic

Wang Ziqi; Cui Kai; Ulrich Costabel; Zhang Xiaoju

doi:10.1002/EXP.20210082

Nanotechnology-facilitated vaccine development during the coronavirus disease 2019 (COVID-19) pandemic

Exploration (Beijing). 2022 Jul 21;2(5):20210082. doi: 10.1002/EXP.20210082. Online ahead of print.

Authors

Wang Ziqi¹, Cui Kai^{1

2}, Ulrich Costabel^{1

3}, Zhang Xiaoju¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou Henan China.
² Academy of Medical Science Zhengzhou University Zhengzhou Henan China.
³ Department of Pneumology Ruhrlandklinik University Medicine Essen Essen Germany.

Abstract

Coronavirus disease 2019 (COVID-19) continually poses a significant threat to the human race, and prophylactic vaccination is the most potent approach to end this pandemic. Nanotechnology is widely adopted during COVID-19 vaccine development, and the engineering of nanostructured materials such as nanoparticles has opened new possibilities in innovative vaccine development by improving the design and accelerating the development process. This review aims to comprehensively understand the current situation and prospects of nanotechnology-enabled vaccine development against the COVID-19 pandemic, with an emphasis on the interplay between nanotechnology and the host immune system.

Keywords: COVID‐19 vaccine; SARS‐CoV‐2; nanotechnology.

Publication types

Review